Key result
Continuous intravenous epoprostenol serves as a salvage therapy for severe pulmonary arterial hypertension compared to conventional therapy.
Why the study?
Does continuous intravenous epoprostenol improve outcomes compared to conventional therapy in patients with severe pulmonary arterial hypertension?
Does continuous intravenous epoprostenol improve outcomes compared to conventional therapy in patients with severe pulmonary arterial hypertension?
This paper provides a critical appraisal of the landmark 1996 trial comparing continuous intravenous epoprostenol with conventional therapy for primary pulmonary hypertension.
Appraisal of 1996 epoprostenol RCT highlights methodological limits; leaves open its applicability to current PAH care.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Rousseau et al. (2018) studied this question. Continuous intravenous epoprostenol serves as a salvage therapy for severe pulmonary arterial hypertension compared to conventional therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: